期刊论文详细信息
Frontiers in Neurology 卷:8
Serum Creatinine Distinguishes Duchenne Muscular Dystrophy from Becker Muscular Dystrophy in Patients Aged ≤3 Years: A Retrospective Study
Yiming Sun1  Huili Zhang2  Ruojie He3  Menglong Chen3  Cheng Zhang3  Liang Wang3  Jiqing Cao4  Juan Yang5  Lulu Xiao6 
[1] Department of Health Care, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China;
[2] Department of Neurology, Guangzhou First People’s Hospital, Guangzhou, Guangdong, China;
[3] Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China;
[4] Department of Neurology, Wuhan Central Hospital, Wuhan, Hubei, China;
[5] Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China;
[6] The Department of Tissue Typing Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China;
关键词: Becker muscular dystrophy;    Duchenne muscular dystrophy;    dystrophinopathy;    serum creatinine;    molecular markers;   
DOI  :  10.3389/fneur.2017.00196
来源: DOAJ
【 摘 要 】

Here, we investigated correlations between serum creatinine (SCRN) levels and clinical phenotypes of dystrophinopathy in young patients. Sixty-eight patients with dystrophinopathy at the Neuromuscular Clinic, The First Affiliated Hospital, Sun Yat-sen University, were selected for this study. The diagnosis of dystrophinopathy was based on clinical manifestation, biochemical changes, and molecular analysis. Some patients underwent muscle biopsies; SCRN levels were tested when patients were ≤3 years old, and reading frame changes were analyzed. Each patient was followed up, and motor function and clinical phenotype were assessed when the same patients were ≥4 years old. Our findings indicated that in young patients, lower SCRN levels were associated with increased disease severity (p < 0.01) and that SCRN levels were the highest in patients exhibiting mild Becker muscular dystrophy (BMD) (p < 0.001) and the lowest in patients with Duchenne muscular dystrophy (DMD) (p < 0.01) and were significantly higher in patients carrying in-frame mutations than in patients carrying out-of-frame mutations (p < 0.001). SCRN level cutoff values for identifying mild BMD [18 µmol/L; area under the curve (AUC): 0.947; p < 0.001] and DMD (17 µmol/L; AUC: 0.837; p < 0.001) were established. These results suggest that SCRN might be a valuable biomarker for distinguishing DMD from BMD in patients aged ≤3 years and could assist in the selection of appropriate treatment strategies.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:2次